Table 2.
Summary statistics of demographic and clinical variables by air trapping status
| Demographic and Clinical Variables | Trappers | Non-trappers |
|---|---|---|
| Number of study subjects | 51 | 43 |
| Categorical Variables | Number (Percent) | Number (Percent) |
| Female gender | 24 (47.1%) | 29 (67.4%) |
| Current use of oral steroids | 17 (33.3%) | 9 (20.9%) |
| Current use of inhaled steroids | 41 (87.2%) | 36 (76.7%) |
| High level of neutrophils | 25 (78.1%) | 21 (61.8%) |
| High level of eosinophils | 9 (28.1%) | 10 (29.4%) |
| Ever smoked | 10 (20.0%) | 7 (16.3%) |
| History of GERD | 22 (44.9%) | 11 (28.2%) |
| History of pneumonia | 33 (70.2%) | 16 (40.0%) |
| Severe Asthma | 37 (72.6%) | 23 (53.5%) |
| Atopic | 47 (92.2%) | 30 (69.8%) |
| Continuous Variables | Mean (Standard Deviation) | Mean (Standard Deviation) |
| Age | 39.8 (12.1) | 32.3 (11.8) |
| Percent less −850 | 28.0 (13.9) | 4.5 (2.4) |
| Duration of asthma | 27.2 (13.7) | 17.9 (10.6) |
| Age at onset of asthma | 12.6 (14.2) | 14.3 (14.9) |
| FEV1 percent predicted | 59.4 (21.0) | 80.1( 16.9) |
| FVC percent predicted | 78.6 (20.8) | 90.2 (15.7) |
| FEV1/FVC × 100 | 59.5 (11.8) | 72.3 (10.8) |
| Positive skin reactions (number) | 4.1 (2.6) | 3.1 (3.2) |
| Percent eosinophils (sputum) | 4.1 (5.5) | 6.2 (19.5) |
| Percent eosinophils (BAL) | 1.9 (7.1) | 0.8 (1.4) |
| Percent neutrophils (sputum) | 41.8 (22.6 | 22.6 (19.1) |
| Percent neutrophils (BAL) | 6.0 (6.1) | 1.3 (1.9) |
| IgE level | 257.8 (327.5) | 450.5 (735.6) |
| FeNO | 30.7 (26.2) | 52.9 (48.2) |